LitAlert ~~ GeneLit.com

    • Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    • Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • Breast Cancer Res. 2022 Nov 18;24(1):80. doi: 10.1186/s13058-022-01572-6.
    • Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
    • Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
    • Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.
    • Olaparib as an Experimental Therapy in a BRCA2-mutated Patient with Metastatic Ovarian Adenocarcinoma Originated from Liver Cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Nov 18;12:1010158. doi: 10.3389/fonc.2022.1010158.
    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Details Emerge About Why Cancers Caused by BRCA Mutations Recur.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 16.

    •• Original research:

    Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.

    • Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    • Rémond MS, Pellat A, Brezault C, Dhooge M, Coriat R.
    • ESMO Open. 2022 Nov 15;7(6):100638. doi: 10.1016/j.esmoop.2022.100638. Epub ahead of print.